Developer docs
API playgroundTry for free, no card

Search company profiles

Poxel

Full company profile

uuid0004j5j

Namestring
Poxel
Legal namestring
Poxel SA
Websiteurl
poxelpharma.com
Company typeenum
Public
Founded yearint
2009
Descriptiontext

Poxel SA is a French clinical-stage biopharmaceutical company founded in 2009 and listed on Euronext Paris (ticker: POXEL), headquartered in Lyon with subsidiaries in Boston and Tokyo. The company develops treatments for chronic serious diseases with metabolic pathophysiology, anchored on a mitochondrial-dysfunction targeting platform spanning type 2 diabetes, NASH/MASH, and rare metabolic diseases including adrenomyeloneuropathy and autosomal dominant polycystic kidney disease.

Its pipeline consists of three principal assets: (1) TWYMEEG (Imeglimin), a first-in-class oral therapy targeting mitochondrial dysfunction, approved in Japan in 2021 for type 2 diabetes and marketed by Sumitomo Pharma, with an expanded label covering renal-impaired patients (eGFR <45) approved by the PMDA in April 2025; (2) PXL065, a deuterium-stabilized R-pioglitazone that met its primary endpoint in the Phase 2 DESTINY-1 trial for MASH and is being developed for hypertrophic cardiomyopathy, holding FDA Orphan Drug and Fast Track Designations for adrenomyeloneuropathy; and (3) PXL770, a first-in-class direct AMPK activator divested to Scynexis in March 2026 for up to $196 million for ADPKD development.

Poxel's revenue model is asset-light and partnership-driven: it receives tiered royalties of 8-18% on TWYMEEG net sales in Japan (net of an 8% payable to Merck Serono, with positive net royalties above 8% allocated to OrbiMed bond repayment) plus sales-based milestones, supplemented by one-time proceeds from asset divestitures and non-dilutive royalty monetizations. The company reported €5.0 million in FY2025 revenue, down from €6.6 million in FY2024 which included a one-time milestone. The company emerged from judicial reorganization proceedings under a court-approved continuation plan in January 2026 and appointed a new CEO, Yves Decadt, effective June 10, 2026.

Short descriptiontext

Poxel SA is a French clinical-stage biopharmaceutical company developing first-in-class therapies for metabolic diseases including type 2 diabetes, NASH/MASH, and rare disorders, generating revenue primarily through tiered royalties on TWYMEEG sales in Japan via Sumitomo Pharma.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLyon, France
HQ citystring
Lyon
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
metabolic disease therapeutics, type 2 diabetes treatment, NASH MASH therapeutics, rare disease drug development, mitochondrial dysfunction drugs
Industry1 code
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds524292
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Metabolic Disease Biopharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1TWYMEEG Royalties
TypeLicensing Royalties
Description

Poxel receives tiered royalties of 8-18% on TWYMEEG net sales in Japan from Sumitomo Pharma. Royalty rate increases to 10% when net sales exceed JPY 5 billion annually, and to 12% when net sales exceed JPY 10 billion. Positive net royalties (above 8% paid to Merck Serono) are allocated to OrbiMed bond repayment.

ir.poxelpharma.com
2PXL770 Asset Sale
TypeOne Time License
Description

Divested PXL770 to Scynexis for up to $196 million, including $8 million upfront payment, up to $8 million in development milestones, and up to $180 million in commercial milestones based on ADPKD sales achievements.

businesswire.com
3OrbiMed Royalty Monetization
TypeLicensing Royalties
Description

Received USD 50 million in bonds by monetizing a portion of future TWYMEEG royalties from Japan. Non-dilutive financing arrangement with proceeds used for debt reduction and rare disease activities.

businesswire.com
4Milestone Payments
TypeLicensing Royalties
Description

Contractual milestone payments including JPY 1 billion (approximately €5.5 million) when TWYMEEG net sales exceed JPY 10 billion threshold, triggering increased royalty rate from 10% to 12%.

ir.poxelpharma.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1TWYMEEG
Description

Brand name for Imeglimin, marketed in Japan by Sumitomo Pharma for treatment of type 2 diabetes

poxelpharma.com
+1 more record
Core offering1 text field

Poxel develops first-in-class pharmaceutical products targeting mitochondrial dysfunction and metabolic pathways for chronic serious diseases. Its commercial product TWYMEEG (Imeglimin) is approved in Japan for type 2 diabetes and marketed through partner Sumitomo Pharma. Pipeline assets include PXL065 (deuterium-stabilized R-pioglitazone for NASH/MASH and HCM) and PXL770 (AMPK activator divested to Scynexis for ADPKD). The company generates revenue through royalties, milestone payments, and asset divestitures.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • TWYMEEG net sales increased 36% YoY in Q1 2026 to JPY 2.3 billion
+2 more records
Product overview1 text field

Poxel is a clinical-stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology. The company's portfolio consists of three main products: TWYMEEG (Imeglimin), a first-in-class mitochondrial dysfunction-targeting product already marketed in Japan for type 2 diabetes by partner Sumitomo Pharma; PXL065, a deuterium-stabilized R-pioglitazone in Phase 2 development for MASH and hypertrophic cardiomyopathy; and PXL770, a first-in-class direct AMPK activator that was divested to Scynexis in March 2026 for ADPKD development. The company operates under a continuation plan approved by the Lyon Commercial Court in January 2026, with headquarters in Lyon, France and subsidiaries in Boston, MA and Tokyo, Japan.

Product and service2 records
1TWYMEEG (Imeglimin)
CategoryType 2 Diabetes Therapeutics
Description

First-in-class oral antidiabetic drug targeting mitochondrial dysfunction, approved in Japan for the treatment of type 2 diabetes. Marketed in Japan by Sumitomo Pharma since 2021, with Poxel receiving tiered royalties of 8-18% on net sales and sales-based milestone payments.

2PXL065
CategoryMASH/NASH and Rare Disease Therapeutics
Description

Deuterium-stabilized R-pioglitazone in clinical development for metabolic dysfunction-associated steatohepatitis (MASH/NASH) and hypertrophic cardiomyopathy (HCM). Met its primary endpoint in the Phase 2 DESTINY-1 trial for NASH. Has received FDA Orphan Drug Designation and Fast Track Designation for adrenomyeloneuropathy (AMN).

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-31
Description

Asset purchase agreement for PXL770 (renamed SCY-770). Scynexis acquired PXL770 for up to $196 million, including $8 million upfront, up to $8 million development milestones, and up to $180 million commercial milestones. Scynexis will develop PXL770 for autosomal dominant polycystic kidney disease (ADPKD), with Phase 2 POC study expected to begin Q4 2026.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Strategic partnership for Imeglimin commercialization in Japan. Sumitomo Pharma markets TWYMEEG for type 2 diabetes treatment. Poxel receives tiered royalties of 8-18% on net sales. Royalty rate increases when sales thresholds are met. Sumitomo conducts post-marketing studies including TWINKLE study in patients with renal impairment.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Small clinical-stage biopharma developing nomacopan for rare inflammatory diseases — comparable in scale, focus on rare disease indications, and small-cap public market profile.

TypeDirect peer
Description

US clinical-stage biopharma with Rezdiffra (resmetirom), the first FDA-approved MASH therapy — directly comparable indication (MASH/NASH) and late-stage clinical profile.

TypeDirect peer
Description

US clinical-stage biopharma developing VK2809 for MASH and obesity candidates — comparable metabolic-disease focus, mid-stage clinical pipeline, and small-cap public profile.

TypeDirect peer
Description

Specialty biopharma historically focused on NASH (obeticholic acid) before strategic restructuring — comparable NASH-focused clinical asset history and small-cap status.

TypeEmerging player
Description

Clinical-stage biopharma developing Aramchol for MASH/NASH — directly comparable indication and small-cap public profile.

TypeDirect peer
Description

Clinical-stage biopharma developing leriglitazone for X-linked adrenoleukodystrophy (ALD) — direct comparator for Poxel's PXL065/PXL770 AMN program in the same ultra-rare disease.

TypeEmerging player
Description

Clinical-stage biopharma developing therapies for metabolic and ophthalmic diseases including MASH candidates — overlapping metabolic-disease pipeline focus.

TypeBroad incumbent
Description

Large Japanese pharma that markets TWYMEEG/Imeglimin for Poxel in Japan — directly relevant as both commercial partner and reference point for pricing/launch of Imeglimin-class therapies in Asia.

TypeDirect peer
Description

French clinical-stage biopharma (Euronext-listed) developing lanifibranor for MASH — directly comparable in geography, stage, and metabolic/NASH focus to Poxel.

TypeDirect peer
Description

French clinical-stage biopharma historically focused on NASH/MASH with elafibranor and diagnostic programs — closely comparable in geography, metabolic disease focus, and Euronext listing.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Poxel

Metabolic Disease Biopharmaceuticalspoxelpharma.com

Poxel SA is a French clinical-stage biopharmaceutical company developing first-in-class therapies for metabolic diseases including type 2 diabetes, NASH/MASH, and rare disorders, generating revenue primarily through tiered royalties on TWYMEEG sales in Japan via Sumitomo Pharma.

What Poxel does

Poxel SA is a French clinical-stage biopharmaceutical company founded in 2009 and listed on Euronext Paris (ticker: POXEL), headquartered in Lyon with subsidiaries in Boston and Tokyo. The company develops treatments for chronic serious diseases with metabolic pathophysiology, anchored on a mitochondrial-dysfunction targeting platform spanning type 2 diabetes, NASH/MASH, and rare metabolic diseases including adrenomyeloneuropathy and autosomal dominant polycystic kidney disease.

Its pipeline consists of three principal assets: (1) TWYMEEG (Imeglimin), a first-in-class oral therapy targeting mitochondrial dysfunction, approved in Japan in 2021 for type 2 diabetes and marketed by Sumitomo Pharma, with an expanded label covering renal-impaired patients (eGFR <45) approved by the PMDA in April 2025; (2) PXL065, a deuterium-stabilized R-pioglitazone that met its primary endpoint in the Phase 2 DESTINY-1 trial for MASH and is being developed for hypertrophic cardiomyopathy, holding FDA Orphan Drug and Fast Track Designations for adrenomyeloneuropathy; and (3) PXL770, a first-in-class direct AMPK activator divested to Scynexis in March 2026 for up to $196 million for ADPKD development.

Poxel's revenue model is asset-light and partnership-driven: it receives tiered royalties of 8-18% on TWYMEEG net sales in Japan (net of an 8% payable to Merck Serono, with positive net royalties above 8% allocated to OrbiMed bond repayment) plus sales-based milestones, supplemented by one-time proceeds from asset divestitures and non-dilutive royalty monetizations. The company reported €5.0 million in FY2025 revenue, down from €6.6 million in FY2024 which included a one-time milestone. The company emerged from judicial reorganization proceedings under a court-approved continuation plan in January 2026 and appointed a new CEO, Yves Decadt, effective June 10, 2026.

Poxel firmographics

Firmographics
Name
Poxel
Legal name
Poxel SA
Website
https://poxelpharma.com
Company type
Public
Founded year
2009
Operating status
Operating
Headcount range
11–50 employees
Short description
Poxel SA is a French clinical-stage biopharmaceutical company developing first-in-class therapies for metabolic diseases including type 2 diabetes, NASH/MASH, and rare disorders, generating revenue primarily through tiered royalties on TWYMEEG sales in Japan via Sumitomo Pharma.
Ownership category
akta.pro rank

Poxel industry classification

Industry
Product category
Metabolic Disease Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds (524292)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Metabolic disease therapeutics
  • Type 2 diabetes treatment
  • NASH MASH therapeutics
  • Rare disease drug development
  • Mitochondrial dysfunction drugs

Where Poxel is headquartered

Location

Headquarters

HQ city
Lyon
HQ country
France
HQ region
Europe

Offices3 records

Markets served

Poxel business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. TWYMEEG Royalties: Poxel receives tiered royalties of 8-18% on TWYMEEG net sales in Japan from Sumitomo Pharma. Royalty rate increases to 10% when net sales exceed JPY 5 billion annually, and to 12% when net sales exceed JPY 10 billion. Positive net royalties (above 8% paid to Merck Serono) are allocated to OrbiMed bond repayment.
  2. PXL770 Asset Sale: Divested PXL770 to Scynexis for up to $196 million, including $8 million upfront payment, up to $8 million in development milestones, and up to $180 million in commercial milestones based on ADPKD sales achievements.
  3. OrbiMed Royalty Monetization: Received USD 50 million in bonds by monetizing a portion of future TWYMEEG royalties from Japan. Non-dilutive financing arrangement with proceeds used for debt reduction and rare disease activities.
  4. Milestone Payments: Contractual milestone payments including JPY 1 billion (approximately €5.5 million) when TWYMEEG net sales exceed JPY 10 billion threshold, triggering increased royalty rate from 10% to 12%.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Poxel product offering

Product offering

Core offering

Poxel develops first-in-class pharmaceutical products targeting mitochondrial dysfunction and metabolic pathways for chronic serious diseases. Its commercial product TWYMEEG (Imeglimin) is approved in Japan for type 2 diabetes and marketed through partner Sumitomo Pharma. Pipeline assets include PXL065 (deuterium-stabilized R-pioglitazone for NASH/MASH and HCM) and PXL770 (AMPK activator divested to Scynexis for ADPKD). The company generates revenue through royalties, milestone payments, and asset divestitures.

Product overview

Poxel is a clinical-stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology. The company's portfolio consists of three main products: TWYMEEG (Imeglimin), a first-in-class mitochondrial dysfunction-targeting product already marketed in Japan for type 2 diabetes by partner Sumitomo Pharma; PXL065, a deuterium-stabilized R-pioglitazone in Phase 2 development for MASH and hypertrophic cardiomyopathy; and PXL770, a first-in-class direct AMPK activator that was divested to Scynexis in March 2026 for ADPKD development. The company operates under a continuation plan approved by the Lyon Commercial Court in January 2026, with headquarters in Lyon, France and subsidiaries in Boston, MA and Tokyo, Japan.

Differentiator

Problem solved

Functional benefit

Brands

  • TWYMEEG: Brand name for Imeglimin, marketed in Japan by Sumitomo Pharma for treatment of type 2 diabetes
  • SmartATM

Products and services

  • TWYMEEG (Imeglimin) First-in-class oral antidiabetic drug targeting mitochondrial dysfunction, approved in Japan for the treatment of type 2 diabetes. Marketed in Japan by Sumitomo Pharma since 2021, with Poxel receiving tiered royalties of 8-18% on net sales and sales-based milestone payments.
  • PXL065 Deuterium-stabilized R-pioglitazone in clinical development for metabolic dysfunction-associated steatohepatitis (MASH/NASH) and hypertrophic cardiomyopathy (HCM). Met its primary endpoint in the Phase 2 DESTINY-1 trial for NASH. Has received FDA Orphan Drug Designation and Fast Track Designation for adrenomyeloneuropathy (AMN).

Quantifiable outcome

  • TWYMEEG net sales increased 36% YoY in Q1 2026 to JPY 2.3 billion
  • +2 more outcomes

Companies that use Poxel

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Poxel technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Poxel partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • SCYNEXIScoreStrategic or Co-development Partner · 31 March 2026Asset purchase agreement for PXL770 (renamed SCY-770). Scynexis acquired PXL770 for up to $196 million, including $8 million upfront, up to $8 million development milestones, and up to $180 million commercial milestones. Scynexis will develop PXL770 for autosomal dominant polycystic kidney disease (ADPKD), with Phase 2 POC study expected to begin Q4 2026.
  • Sumitomo PharmacoreStrategic or Co-development Partner · 1 January 2021Strategic partnership for Imeglimin commercialization in Japan. Sumitomo Pharma markets TWYMEEG for type 2 diabetes treatment. Poxel receives tiered royalties of 8-18% on net sales. Royalty rate increases when sales thresholds are met. Sumitomo conducts post-marketing studies including TWINKLE study in patients with renal impairment.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Poxel competitors and assessment

Company assessment

Emerging players

  • Akari Therapeutics: Small clinical-stage biopharma developing nomacopan for rare inflammatory diseases — comparable in scale, focus on rare disease indications, and small-cap public market profile.
  • Galmed Pharmaceuticals: Clinical-stage biopharma developing Aramchol for MASH/NASH — directly comparable indication and small-cap public profile.
  • NGM Biopharmaceuticals: Clinical-stage biopharma developing therapies for metabolic and ophthalmic diseases including MASH candidates — overlapping metabolic-disease pipeline focus.

Direct peers

  • Madrigal Pharmaceuticals: US clinical-stage biopharma with Rezdiffra (resmetirom), the first FDA-approved MASH therapy — directly comparable indication (MASH/NASH) and late-stage clinical profile.
  • Viking Therapeutics: US clinical-stage biopharma developing VK2809 for MASH and obesity candidates — comparable metabolic-disease focus, mid-stage clinical pipeline, and small-cap public profile.
  • Intercept Pharmaceuticals: Specialty biopharma historically focused on NASH (obeticholic acid) before strategic restructuring — comparable NASH-focused clinical asset history and small-cap status.
  • Minoryx Therapeutics: Clinical-stage biopharma developing leriglitazone for X-linked adrenoleukodystrophy (ALD) — direct comparator for Poxel's PXL065/PXL770 AMN program in the same ultra-rare disease.
  • Inventiva: French clinical-stage biopharma (Euronext-listed) developing lanifibranor for MASH — directly comparable in geography, stage, and metabolic/NASH focus to Poxel.
  • Genfit: French clinical-stage biopharma historically focused on NASH/MASH with elafibranor and diagnostic programs — closely comparable in geography, metabolic disease focus, and Euronext listing.

Broad incumbents

  • Sumitomo Pharma: Large Japanese pharma that markets TWYMEEG/Imeglimin for Poxel in Japan — directly relevant as both commercial partner and reference point for pricing/launch of Imeglimin-class therapies in Asia.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Poxel financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Poxel leadership team

Management profile

Number of profiles

Profiles2 records

Poxel subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Poxel funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Poxel M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Poxel

What does Poxel do?

Poxel develops first-in-class pharmaceutical products targeting mitochondrial dysfunction and metabolic pathways for chronic serious diseases. Its commercial product TWYMEEG (Imeglimin) is approved in Japan for type 2 diabetes and marketed through partner Sumitomo Pharma. Pipeline assets include PXL065 (deuterium-stabilized R-pioglitazone for NASH/MASH and HCM) and PXL770 (AMPK activator divested to Scynexis for ADPKD). The company generates revenue through royalties, milestone payments, and asset divestitures.

Is Poxel a public or private company?

Poxel is a public company. It is classified as public and is currently operating.

When was Poxel founded?

Poxel was founded in 2009. It employs 11 to 50 people.

Where is Poxel based?

Poxel is headquartered in Lyon, France, in the Europe region.

How does Poxel make money?

Four revenue lines are on record. TWYMEEG Royalties are the primary driver. The others are PXL770 Asset Sale, orbiMed Royalty Monetization and milestone Payments.

Who are Poxel's main competitors?

Emerging players on record are Akari Therapeutics, Galmed Pharmaceuticals and NGM Biopharmaceuticals. Direct peers are Madrigal Pharmaceuticals, Viking Therapeutics, Intercept Pharmaceuticals, Minoryx Therapeutics, Inventiva and Genfit. Sumitomo Pharma is listed as a broad incumbent.

Does Poxel have an API?

No public API is recorded for Poxel.

What industry is Poxel in?

Poxel's product category is Metabolic Disease Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogPoxel Reports Revenue for the Third Quarter of 2026Poxel reported consolidated revenue of €1,951k for Q3 2026, up from €1,292k, with TWYMEEG net sales in Japan reaching JPY 2.9B, up 29% year-over-year. The company expects TWYMEEG sales to exceed JPY 10B in fiscal year 2026, triggering a 12% royalty rate and a JPY 1B bonus.MorningstarLaure-Hélène Mercier Co-Opted as Chair of the Board of Directors of PoxelPoxel appointed Laure-Hélène Mercier as chair of its board, effective September 3, 2026, replacing Sophie Jacq Lapointe. The company also announced the sale of PXL770 to Scynexis for up to $196 million, with an upfront payment of $8 million.AInvestWhat Poxel's Share Capital Update Actually Reveals About Who Owns WhatPoxel's share count rose from 53.8 million to 63.2 million, with IPF Partners holding about 29.9% to avoid a mandatory bid. The company's imeglimin drug sales grew 34% in Japan, but royalties flow to OrbiMed, and a warrant facility could dilute existing shareholders further.Business Wire BlogPoxel Publishes Its Turnover for the Second Quarter of 2026 and Announces the Postponement of the Publication of Its 2025 Financial StatementsPoxel SA published Q2 2026 consolidated turnover of €1,237,000, with TWYMEEG net sales in Japan reaching 2.9 billion yen (€15.5 million) in the quarter, representing 32% growth year-over-year. The company also announced the postponement of its 2025 financial statements due to complexity in valuing debt under IFRS as of year-end 2025, compounded by first-quarter 2026 transactions including a BSA facility with IRIS, IPF debt restructuring, and disposal of PXL770. Sumitomo Pharma forecasts TWYMEEG net sales could exceed 10 billion yen in fiscal 2026, which would trigger a 1 billion yen bonus for Poxel and increase the royalty rate from 10% to 12%.AInvestPoxel publishes its turnover for the second quarter of 2026 and announces the postponement of the publication of its 2025 financial statementsPoxel SA reported Q2 2026 revenue of €2.4 million from continued TWYMEEG® sales in Japan under its licensing agreement with Sumitomo Pharma, with a 12% royalty rate now in effect after net sales surpassed ¥10 billion in 2025. The company announced the postponement of its 2025 annual financial statements and disclosed it remains under receivership initiated in August 2025, with the six-month observation period set to conclude in February 2026, amid significant uncertainty about its ability to continue as a going concern. Poxel's new management is pursuing new partnerships for commercialization of its key assets, Imeglimine in Asia and PXL770 for ADPKD, as part of its recovery plan.AInvestPoxel Q2 revenue EUR 1.237 millionPoxel SA reported second-quarter revenue of EUR 1.237 million for the period ending June 30, 2026, reflecting continued operational activity during its ongoing restructuring. The company has executed multiple strategic steps to strengthen its balance sheet, including the sale of its PXL770 asset to Scynexis for up to $196 million, a drawdown of additional Tranche D PDR bonds, and an equity line with IRIS Capital, all of which have been reinforced by the Commercial Court of Lyon's approval of its recovery plan.Pulse 2.0Poxel Appoints Yves Decadt As CEO To Advance Portfolio Development And Strategic PartnershipsPoxel appointed Yves Decadt as CEO effective June 10, 2026, to advance its portfolio development and strategic partnerships as part of its Continuation Plan. Decadt, with over 25 years of industry experience, aims to accelerate partnership discussions for Imeglimin outside Japan and develop key assets including PXL065.Business Wire BlogPoxel Appoints Yves Decadt as Chief Executive Officer to Accelerate Portfolio Development and Strategic PartnershipsPoxel appointed Yves Decadt as CEO effective 10 June 2026, succeeding Nicolas Trouche. His priorities include accelerating Imeglimin partnerships outside Japan and developing PXL065 for HCM and MASH. He will continue serving on the board.Business Wire BlogPoxel Reports First Quarter 2026 Revenue and Provides a Business UpdatePoxel reported consolidated revenue of €1.277 million for Q1 2026, representing a 20% increase compared to Q1 2025, driven by 36% growth in TWYMEEG® net sales in Japan reaching JPY 2.3 billion. Sumitomo Pharma projects TWYMEEG® sales to exceed the JPY 10 billion threshold during fiscal year 2026, which would trigger a JPY 1 billion milestone payment to Poxel and increase the royalty rate from 10% to 12%. Poxel also announced the divestment of PXL770 to Scynexis for total potential consideration of up to $196 million, including an $8 million upfront payment.BioSpacePoxel: Postponement of the Publication of the 2025 Annual Financial Statements and the Annual Financial ReportPoxel SA postponed publication of its 2025 annual financial statements and report, with approval set for June 5, 2026 and publication for June 15, 2026. The delay stems from accounting treatment of an equity financing facility with IRIS and a PDR subscription with IPF Invest, plus the sale of PXL770 to Scynexis.